US biopharma Eikon Therapeutics plans to go public via an IPO on the Nasdaq, following in the footsteps of Aktis ...
Biotechnology company Eikon Therapeutics announced the initial closing of a $350.7 million Series D financing round that it will use to advance its clinical-stage programs. The new funding brings the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback